BIO-TECHNE Corp
TECH- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000842023
No open-market purchases or sales by BIO-TECHNE Corp insiders were filed in the last 90 days; 597 institutions reported holding it in 13F filings for Q2 2026, worth $12.3B in total; 3 superinvestors hold it, including Maverick Capital and Weitz Investment Management.
Q2 2024 vs. Q1 2024
How the institutions holding BIO-TECHNE Corp changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Of which not filed for Q2 2024 | Q2 2024 | Change |
|---|---|---|---|---|
| Holders | 556 | 5 | 573 | +22 |
| Shares | 158.6M | 297.0K | 155.9M | −2.40M (−1.5%) |
| Value | $11.2B | $20.9M | $11.2B | +$28.0M (+0.3%) |
5 institutions that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (67)
Institutions that held BIO-TECHNE Corp at the end of Q2 2024 but not at the end of Q1 2024.
Sold out (45)
Institutions that held BIO-TECHNE Corp at the end of Q1 2024 and filed for Q2 2024 without it.
Not filed for Q2 2024 yet (5)
Institutions that held BIO-TECHNE Corp at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Credit Suisse AG | 257,045 | $18.1M |
| Fjarde Ap-Fonden /Fourth Swedish National Pension Fund | 21,400 | $1.51M |
| Degroof Petercam Asset Management | 13,300 | $936.2K |
| Handelsinvest Investeringsforvaltning | 4,511 | $318.0K |
| Shell Asset Management Co | 764 | $55.0K |